We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience, read our Cookie Policy

The First Discovery of a Single Digit Nanomolar Small Molecule Blocker of a Protein-protein Interaction Target

Video   Jul 03, 2015

 



About the Speaker
Dr. Nils Hansen is the CEO and founder of Vipergen ApS. He is the principal inventor of the enabling YoctoReactor® and Binder Trap Enrichment® drug discovery technology platforms. He previously worked for Praecis Pharmaceuticals Inc., (Waltham, MA, USA) and Symphogen A/S, (Copenhagen, Denmark). Dr. Hansen earned his Ph.D. in immunology from the University of Copenhagen, Denmark in 2000 and his M.Sc. in Chemistry and Biotechnology from the University of Aarhus, Denmark in 1996.Abstract
Effective small molecule PPI blocker discovery using high fidelity DNA-encoded libraries and a low-noise homogeneous screening assay. The screen employs a unique principle of trapping small molecule binders together with the protein target in miniscule droplets.

 
 
 
 

Recommended Videos

Top Science Stories of 2018

Video

We have seen some amazing scientific breakthroughs in 2018. Here is a selection of our favorites.

WATCH NOW

The Science of Christmas

Video

Does Rudolph's nose really glow? Why doesn't anybody see Santa deliver presents? Modern science can help you explain the mysteries of Santa to your kids!

WATCH NOW

Researchers love this microplate spectrophotometer - Thermo Scientific Multiskan Sky

Video

Plate reader with ready-made protocols, cloud connected, touch screen, no learning curve. Researchers from the University of Helsinki Pharmacy dept. review the Thermo Scientific Multiskan Sky Microplate Spectrophotometer as efficient and easy-to-use.

WATCH NOW

 

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE